'The Facts'

Mesoblast (ASX:MSB) has taken a step toward expanding the use of its flagship cell therapy Ryoncil, announcing a significant collaboration with the U.S. National Institutes of Health–funded Blood and Marrow Transplant Clinical Trials Network to conduct a pivotal trial in adults with severe steroid-refractory acute graft versus host disease.

Syntara CEO Gary Phillips said the new Australian study offers a significant opportunity to expand the therapeutic potential of amsulostat.

Alterity Therapeutics (ASX:ATH) has marked a turning point in its corporate history, with longtime Chairman and company founder Geoffrey Kempler delivering his final address at the 2025 Annual General Meeting.

The Federal Government has formally blocked the proposed acquisition of Mayne Pharma by US company Cosette, following advice from the Foreign Investment Review Board

The final in a series on the need to formally prioritise patient input in HTA decision-making, we argue that the system currently lacks the ethical framework necessary to make morally defensible decisions. No system of decision-making can be considered ethical when its rules, when properly applied, lead to outcomes that delay access to treatment with consequent suffering, harm, and in some cases, death.

If patient experience continues to sit outside the statutory framework, if it remains something the institution may consider but is never required to weigh, then the system will continue to fail to meet a human ethical standard.

A new analysis from Telix Pharmaceuticals (ASX:TLX) has found that its investigational kidney cancer imaging agent TLX250-CDx could meaningfully alter clinical management for almost half of patients presenting with indeterminate renal masses.

Amplia Therapeutics (ASX:ATX) has moved a step closer to a pivotal clinical program for its lead FAK inhibitor, narmafotinib, after receiving favourable feedback from the US Food and Drug Administration.

AFT Pharmaceuticals (ASX:AFP) has delivered its 10th consecutive first-half revenue increase, reporting a strong performance for the six months to 30 September 2025 as investment in international expansion and late-stage R&D begins to pay off.

Alcon has strengthened its Australia and New Zealand leadership team with the appointment of Ronak Patel as Head of Commercial Management, Vision Care.

Consider a world in which an advisory committee oversaw PBS decision-making, comprising 21 representatives of only patient organisations and clinicians, and operated under a statutory framework requiring it to weigh the human and clinical impact of its advice against the government’s fiscal interests.

Vertex Pharmaceuticals has received approval from the Therapeutic Goods Administration for ALYFTREK, a once-daily, next-generation CFTR modulator for Australians living with cystic fibrosis.